Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Inclusion Criteria:

- Diagnosis of Non-Squamous Non-Small Cell Lung Cancer

- Receipt of at least one but not more than two prior treatment regimens in the advanced
setting

- Prior treatment with PD-1/PD-L1 checkpoint inhibitor therapy and platinum-based
chemotherapy in combination or in sequence (i.e., platinum-based chemotheraphy
followed by checkpoint inhibitor therapy)

- Most recent treatment regimen must have included a checkpoint inhibitor therapy with
radiographic disease progression on or after treatment

- Candidate to receive docetaxel as second or third line therapy

Exclusion Criteria:

- Uncontrolled brain metastases

- Tumors that have tested positive for EGFR, ROS1, ALK mutations, or ALK fusions

- Unacceptable toxicity with prior checkpoint inhibitor therapy

- Receipt of systemic anti-cancer therapy post checkpoint inhibitor therapy, other than
maintenance chemotherapy

- Impaired heart function